Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.
about
Switching treatments in haemophilia: is there a risk of inhibitor development?Present and future challanges in the treatment of haemophilia: a clinician's perspectiveThe current state of adverse event reporting in hemophilia.A new recombinant factor VIII: from genetics to clinical use.Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyInhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice.Plasma exchange and immunosuppressive therapy in a case of mild haemophilia A with inhibitors and a life-threatening lower limb haemorrhage.CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.The hope and reality of long-acting hemophilia products.The modern treatment of haemophilia: a narrative reviewPurchasing factor concentrates in the 21st century through competitive tendering.Blood Clotting Factor VIII: From Evolution to Therapy.Factor VIII therapy for hemophilia A: current and future issues.Inhibitors - genetic and environmental factors.Non-genetic risk factors and their influence on the management of patients in the clinic.Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH.Emerging drugs for the treatment of hemophilia A and B.Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Predictive immunogenicity of Refacto AF.The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.Concentrate-related inhibitor risk: is a difference always real?Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII.The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade.How I treat inhibitors in haemophilia.
P2860
Q27001016-AA023FD3-F15B-49E7-93F9-52304C771C3EQ27026137-08147F97-A9DE-449E-8E08-8251CA5C2C98Q30239952-F3AD8A42-56E2-4AF8-9287-66FC5F91CED2Q30370282-A3AF58DE-6518-47C2-855E-1120B9CFB303Q34283156-2A9C5A88-5349-4282-B850-B575EA7811A2Q34416394-01A295A0-5A1E-41E6-9747-969C4C0F5750Q34784564-32CD6614-AAA1-4881-8F12-A8B96A4A69F0Q35209354-E726C03B-A146-4D93-BD65-5311211E52A1Q36644270-AE326CE2-CCEF-43ED-87C4-B6E8C59B9FF1Q37588914-1422E2DC-E758-4CA9-BA4F-8F5A077B4E4EQ37702710-339BD5A8-7727-4485-A182-8EE8568F704AQ37990479-570E4E66-51E4-4939-9CAE-66B968E6F861Q38025882-841228AF-03FA-495A-9812-3E8C0CA2A865Q38109706-021270FD-C480-43F3-B945-5A13B1E5CEC9Q38118763-3C53E014-90B4-45EE-8083-C37137566155Q38203350-54FF6892-4666-4EAC-815C-5D099DAE4043Q38206856-7A44ED30-EAA2-45EA-844E-F3F9E3FED8D5Q38308194-DDF7D578-48FD-4808-B09B-CE1BA839CC29Q38833988-30125669-2685-4779-8745-DA56DC43A187Q38933707-0EC709E1-1853-4972-88F4-BD488C4A0EBBQ38958322-22B7B4FF-0F83-470A-8D8B-88CA9AAC39CDQ39167965-4A3B7B7F-0C8E-4E68-BCAE-A0074E3EBAFDQ45838031-77DC92BB-5311-44DC-B7F1-9EC2FA1B1B4EQ45861147-6D505E4D-4C50-4C10-B292-E7674330F0A3Q45870049-363F93F3-7728-4815-B1CF-2D14B2638446Q45872627-A265D202-6541-4E03-997F-46EAE8BDEF67Q45872871-B07CD96B-1701-4571-800C-CBDDEE046CB4Q45878736-3DE7E31D-71A0-4876-B166-D8B598C307CFQ45879927-22BB380C-201C-407C-BFB9-F2D86AFDFE29
P2860
Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Can B-domain deletion alter th ...... prospective clinical studies.
@en
Can B-domain deletion alter th ...... prospective clinical studies.
@nl
type
label
Can B-domain deletion alter th ...... prospective clinical studies.
@en
Can B-domain deletion alter th ...... prospective clinical studies.
@nl
prefLabel
Can B-domain deletion alter th ...... prospective clinical studies.
@en
Can B-domain deletion alter th ...... prospective clinical studies.
@nl
P2093
P2860
P1476
Can B-domain deletion alter th ...... prospective clinical studies.
@en
P2093
L M Aledort
M M Wilkes
R J Navickis
P2860
P304
P356
10.1111/J.1538-7836.2011.04472.X
P577
2011-11-01T00:00:00Z